Rett Syndrome Clinical Trial
Official title:
Pathogenesis of Rett Syndrome: Natural History and Treatment
Rett syndrome (RTT) is a disorder in which the nervous system does not develop properly. RTT generally affects girls, but there are some boys who have been diagnosed with RTT. Symptoms of RTT include small brain size, poor language skills, repetitive hand movements, and seizures. This study will evaluate the effectiveness of two drugs in treating the symptoms of RTT.
RTT is a neurodevelopmental disorder characterized by apparently normal early development
followed by loss of purposeful hand use, distinctive hand stereotypies, slowed brain growth,
loss of language, respiratory irregularities, GI disturbances, gait abnormalities, seizures,
and mental retardation. These symptoms appear between ages 6 and 18 months (stage 2 of the
disease) following apparently normal development (stage 1). Subsequently, there is gradual
stabilization of severe mental retardation and motor compromise (stage 3). The majority (70%
to 80%) of patients demonstrate mutations in the methyl-CpG-binding-protein-2 (MeCP2) gene,
a transcription repressor located on chromosome Xq28. The disorder predominantly affects
females, but a few males with mutations in MeCP2 have been identified, even though many of
them do not have the classic symptoms recognized in females.
Recent studies demonstrate increased brain N-methyl-D-aspartate (NMDA) receptors in stages 2
and 3 of the disease. This age-specific increase in glutamate levels and their receptors
contribute to brain damage. This first study will examine the effectiveness of
dextromethorphan, an NMDA receptor antagonist, to ameliorate symptoms. Participants will be
randomized to receive one of three doses of dextromethorphan. All participants will be
admitted to the hospital for three days at the beginning of the study. During the
hospitalization, participants will undergo physical exam, Dexascan, MRI, EEG, behavioral
assessment, laboratory testing, and neuropsychological evaluations. Six months after
baseline assessment, participants will be rehospitalized for 3 days for similar assessments.
Reduction in choline acetyltransferase activity in RTT patients may also contribute to
disturbed cortical development and psychomotor retardation in RTT. Therefore, the second
part of the study will evaluate the effect of donepezil hydrochloride, an inhibitor of
acetylcholine-esterase, on acetylcholine levels. This portion of the study will not begin
until pharmacokinetic data for donepezil in children is available.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04988867 -
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Not yet recruiting |
NCT04014985 -
Patients With RETT Syndrome
|
N/A | |
Not yet recruiting |
NCT04041713 -
A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome
|
Phase 2 | |
Completed |
NCT02705677 -
Biobanking of Rett Syndrome and Related Disorders
|
||
Terminated |
NCT02790034 -
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT05932589 -
Neurophysiologic Biomarkers in Rett Syndrome
|
||
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Completed |
NCT04776746 -
Open-Label Extension Study of Trofinetide for Rett Syndrome
|
Phase 3 | |
Completed |
NCT04181723 -
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢)
|
Phase 3 | |
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT04514549 -
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
|
||
Completed |
NCT02738281 -
Natural History of Rett Syndrome & Related Disorders
|
||
Terminated |
NCT02562820 -
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
|
Phase 1 | |
Completed |
NCT05687214 -
Osteopathic Manipulative Treatment for Constipation in People With Rett Syndrome
|
N/A | |
Recruiting |
NCT06199700 -
Esketamine for the Treatment of Rett Syndrome
|
Early Phase 1 | |
Completed |
NCT03941444 -
ANAVEX2-73 Study in Patients With Rett Syndrome
|
Phase 3 | |
Recruiting |
NCT06346106 -
The Diagnostic Experience of Male Rett Syndrome
|
||
Not yet recruiting |
NCT06338267 -
Validation of Innovative Biosensors for Rett Autonomic Symptom Tracking
|